CA3024643C - Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy - Google Patents

Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy Download PDF

Info

Publication number
CA3024643C
CA3024643C CA3024643A CA3024643A CA3024643C CA 3024643 C CA3024643 C CA 3024643C CA 3024643 A CA3024643 A CA 3024643A CA 3024643 A CA3024643 A CA 3024643A CA 3024643 C CA3024643 C CA 3024643C
Authority
CA
Canada
Prior art keywords
biomarkers
expression
biomarker
extent
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3024643A
Other languages
English (en)
French (fr)
Other versions
CA3024643A1 (en
Inventor
Robert T. Streeper
Sung H. Baek
Eizbieta Izbicka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Prevention and Cure Ltd
Original Assignee
Cancer Prevention and Cure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/403,369 external-priority patent/US8541183B2/en
Application filed by Cancer Prevention and Cure Ltd filed Critical Cancer Prevention and Cure Ltd
Publication of CA3024643A1 publication Critical patent/CA3024643A1/en
Application granted granted Critical
Publication of CA3024643C publication Critical patent/CA3024643C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3024643A 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy Active CA3024643C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/403,369 2009-03-12
US12/403,369 US8541183B2 (en) 2007-09-11 2009-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US23719809P 2009-08-26 2009-08-26
US61/237,198 2009-08-26
CA2755301A CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2755301A Division CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Publications (2)

Publication Number Publication Date
CA3024643A1 CA3024643A1 (en) 2010-09-16
CA3024643C true CA3024643C (en) 2021-08-03

Family

ID=42729154

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3024643A Active CA3024643C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
CA2755301A Active CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2755301A Active CA2755301C (en) 2009-03-12 2010-03-12 Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy

Country Status (10)

Country Link
US (1) US11474104B2 (https=)
EP (4) EP3444359A1 (https=)
JP (7) JP2012520469A (https=)
KR (2) KR101900016B1 (https=)
CN (4) CN108181457B (https=)
AU (3) AU2010223911A1 (https=)
CA (2) CA3024643C (https=)
ES (1) ES2703714T3 (https=)
PL (1) PL3257953T3 (https=)
WO (1) WO2010105235A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681899C (en) 2007-03-27 2018-06-19 Immunovia Ab Methods for diagnosis of pancreatic adenocarcinoma, and biomarkers and arrays for use in the same
EP3825693A1 (en) 2011-04-29 2021-05-26 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
WO2017044715A1 (en) * 2015-09-09 2017-03-16 Somalogic, Inc. Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles
JP6857185B2 (ja) * 2015-09-11 2021-04-14 アプタマー サイエンス インコーポレイテッドＡｐｔａｍｅｒ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
CN108473529B (zh) * 2015-11-10 2023-04-18 伦斯勒中心转化研究公司 检测和治疗肺高压的方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112501140B (zh) * 2020-12-16 2022-03-18 熊猫乳品集团股份有限公司 一种生物活性多肽yfgsgfaapffivrhqllkk及其制备方法和应用
TWI796010B (zh) * 2021-11-23 2023-03-11 國立高雄大學 基質金屬蛋白酶-1胜肽拓印導電聚合物及其用途
CN117907508A (zh) * 2023-12-19 2024-04-19 查理高特(青岛)健康科技有限公司 基于代谢组学的高尿酸血症及尿酸性肾病的风险预测系统

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837529T2 (de) 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
US20070092917A1 (en) 1998-05-01 2007-04-26 Isabelle Guyon Biomarkers for screening, predicting, and monitoring prostate disease
HU229520B1 (en) 1999-02-12 2014-01-28 Scripps Research Inst Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
WO2000052054A2 (en) 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
FI990888A0 (fi) * 1999-04-20 1999-04-20 Medix Biochemica Ab Oy Menetelmä ja testikittejä respiratorisen alueen tulehduksen läsnäolon ja vaikeusasteen arvioimiseksi
EP1224564A1 (en) * 1999-04-26 2002-07-24 Surromed, Inc. Phenotype and biological marker identification system
AU2001276890A1 (en) 2000-07-12 2002-01-21 Glaxo Group Limited Novel compounds
NZ528205A (en) * 2001-03-12 2006-09-29 Monogen Inc Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes
US20030190602A1 (en) 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
EP1801240A1 (en) 2001-06-05 2007-06-27 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
US20030134339A1 (en) 2002-01-14 2003-07-17 Thomas Brown Proteomics based method for toxicology testing
JP2005522228A (ja) 2002-04-11 2005-07-28 オックスフォード グライコサイエンシス （ユーケイ） リミテッド 癌に関与するタンパク質
WO2004030511A2 (en) 2002-05-10 2004-04-15 Eastern Virginia Medical School Prostate cancer biomarkers
AU2003240495A1 (en) * 2002-06-04 2003-12-19 Incyte Corporation Diagnostics markers for lung cancer
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
CN101586155A (zh) * 2002-09-30 2009-11-25 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
JP4723476B2 (ja) 2003-02-14 2011-07-13 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
MXPA05009251A (es) * 2003-03-04 2005-10-19 Wyeth Corp Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias.
CN101265254A (zh) * 2003-03-27 2008-09-17 兰肯瑙医学研究所 新型ido抑制剂及其使用方法
JP2005044330A (ja) 2003-07-24 2005-02-17 Univ Of California San Diego 弱仮説生成装置及び方法、学習装置及び方法、検出装置及び方法、表情学習装置及び方法、表情認識装置及び方法、並びにロボット装置
ATE496142T1 (de) * 2004-03-23 2011-02-15 Oncotherapy Science Inc Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs
CA2561535A1 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20060084126A1 (en) * 2004-10-20 2006-04-20 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer
WO2006045318A2 (en) * 2004-10-27 2006-05-04 Aarhus Universitet Diagnosis and treatment of immune-related diseases
MX2007006441A (es) 2004-11-30 2007-08-14 Johnson & Johnson Prognosis de cancer de pulmon.
CN1300580C (zh) 2004-12-31 2007-02-14 中国人民解放军第306医院 检测肝癌血清特征蛋白的质谱模型及其制备方法和应用
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
US20070099239A1 (en) 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20130108481A (ko) * 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
JPWO2007026773A1 (ja) 2005-08-31 2009-03-12 学校法人 久留米大学 医用診断処理装置
EP1941276A1 (de) 2005-10-29 2008-07-09 Bayer Technology Services GmbH Verfahren zur bestimmung eines oder mehrerer analyten in komplex zusammengesetzten proben biologischen ursprungs und dessen verwendung
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
KR100760518B1 (ko) 2006-07-18 2007-09-20 삼성정밀공업 주식회사 가구용 도어의 닫힘 충격 완충 장치
US7840505B2 (en) 2006-11-02 2010-11-23 George Mason Intellectual Properties, Inc. Classification tool
WO2008063413A2 (en) * 2006-11-13 2008-05-29 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring, and treatment of lung cancer
US8343491B2 (en) * 2006-12-18 2013-01-01 The Johns Hopkins University Anti-HIMF antibodies to treat lung diseases
JP5085927B2 (ja) 2006-12-21 2012-11-28 ウィンテックポリマー株式会社 難燃性樹脂組成物
CN101668774B (zh) * 2007-02-28 2013-06-26 诺维莫尼公司 抗干扰素诱导蛋白-10的抗体及其使用方法
AU2008236634A1 (en) 2007-04-05 2008-10-16 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
CA2681667A1 (en) 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
EP2156187A4 (en) 2007-06-15 2010-07-21 Biosite Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND / OR FORECASTING EGG CANCER AND LUNG CANCER
PL2195645T3 (pl) 2007-09-11 2014-12-31 Cancer Prevention & Cure Ltd Metoda wspomagająca diagnostykę i terapię astmy i rak płuc
US7888051B2 (en) * 2007-09-11 2011-02-15 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
US8541183B2 (en) * 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
JP5159242B2 (ja) 2007-10-18 2013-03-06 キヤノン株式会社 診断支援装置、診断支援装置の制御方法、およびそのプログラム
ES2527649T3 (es) 2007-12-10 2015-01-28 F. Hoffmann-La Roche Ag Panel de marcadores para el cáncer colorrectal
DK2240781T3 (en) 2008-01-18 2018-03-26 Harvard College METHODS FOR DETECTING DISEASE OR STATE SIGNATURES IN BODY FLUIDS
US20110245092A1 (en) 2008-03-04 2011-10-06 John Bilello Diagnosing and monitoring depression disorders based on multiple serum biomarker panels
CN101587125B (zh) 2008-05-21 2013-07-24 林标扬 高表达癌症标记物和低表达组织器官标记物组合试剂盒
CA3152591C (en) 2008-09-09 2023-08-29 Somalogic Operating Co., Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CN101988059B (zh) 2009-07-30 2014-04-02 江苏命码生物科技有限公司 胃癌检测标记物及其检测试剂盒和生物芯片
KR20140024860A (ko) 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트
EP3825693A1 (en) 2011-04-29 2021-05-26 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
WO2015066564A1 (en) 2013-10-31 2015-05-07 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
US20170073763A1 (en) 2014-03-12 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer

Also Published As

Publication number Publication date
JP2022000650A (ja) 2022-01-04
CN113189342A (zh) 2021-07-30
KR20180104190A (ko) 2018-09-19
AU2010223911A1 (en) 2011-10-06
CA2755301A1 (en) 2010-09-16
AU2018202110A1 (en) 2018-04-19
KR20120010229A (ko) 2012-02-02
JP2025114736A (ja) 2025-08-05
KR101900016B1 (ko) 2018-09-20
ES2703714T3 (es) 2019-03-12
EP2406401A2 (en) 2012-01-18
CN113189342B (zh) 2024-12-03
WO2010105235A2 (en) 2010-09-16
PL3257953T3 (pl) 2019-05-31
CA2755301C (en) 2019-01-08
EP2857522A3 (en) 2015-10-14
JP6250600B2 (ja) 2017-12-20
WO2010105235A3 (en) 2011-02-24
JP2024024128A (ja) 2024-02-21
CN102405296A (zh) 2012-04-04
CA3024643A1 (en) 2010-09-16
JP2019158890A (ja) 2019-09-19
AU2016228188B2 (en) 2018-01-04
EP2406401A4 (en) 2013-01-09
JP2012520469A (ja) 2012-09-06
US11474104B2 (en) 2022-10-18
AU2018202110B2 (en) 2020-09-03
KR102061441B1 (ko) 2019-12-31
JP2018072348A (ja) 2018-05-10
JP2016006426A (ja) 2016-01-14
JP6774925B2 (ja) 2020-10-28
EP3257953B1 (en) 2018-09-26
EP3257953A1 (en) 2017-12-20
EP3444359A1 (en) 2019-02-20
AU2016228188A1 (en) 2016-09-29
CN108181457B (zh) 2021-03-30
CN108181457A (zh) 2018-06-19
EP2857522A2 (en) 2015-04-08
US20180356423A1 (en) 2018-12-13
CN104535765A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
AU2018202110B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender- based disease identification, assessment, prevention and therapy
US9933429B2 (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
US7888051B2 (en) Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
EP2781913B1 (en) Method for aiding in the diagnosis and therapy of asthma and lung cancer
WO2009039023A2 (en) Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
HK40058647A (en) Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
HK40058647B (zh) 监定、评估、预防以及治疗肺疾病的方法及试剂盒
AU2011351993A1 (en) Protein biomarkers of late stage breast cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181119

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240911

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240911

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240911

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250228

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250228

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260310